Genetic aspects of Pulmonary Fibrosis by Hadsall, Katie
Creative Components Iowa State University Capstones, Theses and Dissertations 
Spring 2020 
Genetic aspects of Pulmonary Fibrosis 
Katie Hadsall 
khadsall@iastate.edu 
Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents 
 Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons 
Recommended Citation 
Hadsall, Katie, "Genetic aspects of Pulmonary Fibrosis" (2020). Creative Components. 504. 
https://lib.dr.iastate.edu/creativecomponents/504 
This Creative Component is brought to you for free and open access by the Iowa State University Capstones, 
Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative 
Components by an authorized administrator of Iowa State University Digital Repository. For more information, 
please contact digirep@iastate.edu. 
Genetic Aspects of Pulmonary Fibrosis 
Katherine Hadsall 
Dept. of Biomedical Sciences 
Iowa State University College of Veterinary Medicine 
Abstract 
Pulmonary fibrosis is broad term for a group of lung diseases, idiopathic or familial, that results in 
fibroblasts and excess tissue in the lungs. Because it is a generally seen in multiple generations of families, 
it is referred to as familial pulmonary fibrosis. The genetic aspects underlying the disease is unclear; 
however, there are a plethora of proposed genetic mechanisms that have been studied. The most commonly 
proposed genetic mechanisms, involving telomere shortening and surfactant overproduction, will be 
discussed in this review.   
Introduction 
Pulmonary fibrosis (PF) describes a group of interstitial lung diseases that result in the 
accumulation of fibroblasts and tissue in the lung.  PF often results from environmental exposures, such as 
drug toxicity and inhalation of fibrogenic dust, or systemic diseases such as connective tissue disorders, or 
as a sporadic disease1.  Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease, categorized under 
the pulmonary fibrosis designation, resulting in scarring of the lungs due to unknown reasons1, 2.  Prognosis 
of the disease is generally poor, with those diagnosed living an average of 2-5 years after diagnosis.  
Mortality results from progressive, unresolved scarring of the lungs that leads to respiratory 
insufficiency1.  IPF typically presents for the first time in individuals over 50 years of age, and 75 percent 
of people with IPF are males who currently or previously smoked cigarettes2.  Even though the cause of the 
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disease is mostly unknown, up to 20 percent of diagnosed individuals have a family member with the 
disease and thus the disease is referred to as familial pulmonary fibrosis (FPF)1, 2. 
Diagnosis of pulmonary fibrosis can be challenging as symptoms resemble many respiratory 
illnesses, and conventional testing may not show any visible abnormalities until the disease has progressed. 
Typical in pulmonary fibrosis patients is a “honeycomb” lung [Fig1], a distinctive pattern seen on 
computerized tomography (CT) scans1,3.  The appearance of the honeycomb lung shows empty pockets 
(bubbles) where solid lung tissue should be3.  Not only is diagnosis of FPF difficult, so is treatment of the 
disease.   
 
 
 
 
 
 
Figure 1. A,B show a typical computerized tomography (CT) scan displaying the characteristic 
“honeycomb” pattern observed in individuals with pulmonary fibrosis. C,D show the typical lung in a 
healthy adult without pulmonary fibrosis.  
 
 There are no treatments (e.g., medications or procedures) that resolve or even markedly improve 
FPF.  Current treatments are used to slow the progression of lung scarring however they typically do not 
lessen the major symptoms of the disease- dyspnea and chronic cough2.  As the scarring in the lungs 
worsens, symptoms increase in intensity and can have an adverse effect on day-to-day activities such as 
showering, eating, dressing, and walking. Unique to the disease are the abnormalities presented in 
pulmonary function tests, radiographs, and biopsies (e.g., honeycomb pattern)3.   
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The inheritance pattern of the disease is most consistent with autosomal dominant with incomplete 
penetrance, meaning individuals with an implicated genotype may or may not show the disease1, 4, 5.  One 
common hypothesis is that telomere shortening, related to mutations in various genes, precipitates the onset 
of pulmonary fibrosis.  Important to this effect is telomerase, a DNA polymerase that synthesizes new 
telomere repeats onto chromosomal ends4.  Two important parts of this process include TERT, a reverse 
transcriptase, and TERC, a telomerase RNA component. TERT copies the template TERC, undergoes 
translocation, and then adds the successive repeats onto chromosomal ends5.  Mutations in either TERT or 
TERC are the cause of about 8-15 percent of familial pulmonary fibrosis cases5.  
A small percentage of individuals with pulmonary fibrosis that have short telomeres also suffer 
from premature aging syndrome designated as dyskeratosis congenita which also results in aplastic 
anemia—destruction of bone marrow4.  Pulmonary fibrosis and dyskeratosis congenita both share similar 
pathophysiology in that several of the same telomere mutations have been identified in other genes 
including TERT, TERC, DKC1, TINF2, and RTEL11,4,6-8.  The connection between the two diseases further 
provides evidence linking telomeropathy and FPF pathogenesis. 
FPF has also been linked to mutations in another main group of genes: surfactant metabolism genes. 
These genes include SFTPC (surfactant protein C), SFTPA2 (surfactant protein A2) and ABCA3 (ATP-
binding cassette subfamily A, member 3)1,9-12. More specifically, SFTPC mutations have been frequently 
identified in children with idiopathic pneumonias.  Genome sequencing and analysis revealed that half of 
the cases were sporadic and the other half were inherited from parents. Analysis revealed an autosomal 
dominant with incomplete penetrance, congruent with how FPF is inherited12.  
 Another common mutation closely linked to FPF occurs in the gene encoding mucin 5B (MUC5B). 
Extensive genome-wide sequencing identified a single nucleotide polymorphism (SNP) in the promoter 
region of MUC5B in some individuals with FPF13. The role of mucins, glycosylated proteins in mucus, is 
to give mucus its viscoelastic properties13.  Mucus is important in trapping inhaled particles and removing 
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them via coughing or ciliary exportation processes.  It has been shown in several studies that overproduction 
of MUC5B interferes with alveolar repair and reduces lung clearance, thus potentially leading to FPF13.    
In summary, there is substantial evidence that FPF is caused by mutations in either surfactant 
metabolism genes or mutations causing premature telomere shortening.  The following sections will discuss 
evidence for each of these hypotheses by reviewing studies that specifically examine some of the major 
mutations identified in RTEL1, TERT, MUC5B, and SFTPC.  Novel mutations in PARN and ZCCHC8 will 
also be discussed.    
RTEL1 Mutation 
A major mutation associated with premature telomere shortening that has recently emerged is in 
the regulator of telomere elongation helicase 1 (RTEL1) gene.  RTEL1 is an ATP-dependent DNA helicase, 
which plays a major role in DNA replication, genome stability, DNA repair, and telomere maintenance1. 
Several studies have focused on the presence of heterozygous RTEL1 mutations in individuals diagnosed 
with FPF.  In one particular study, that has been cited in a plethora of reviews on FPF, whole-exome 
sequencing revealed heterozygous RTEL1 mutations in individuals diagnosed with FPF, thus solidifying 
the hypothesis that RTEL1 mutations play a role in the onset of FPF1,8. 
Kannengieser, et al. (2015) conducted whole-exome sequencing analysis of 47 patients (35 male) 
from 35 separate families, whom had diagnosed FPF, and found no mutations in the typical genes associated 
with premature telomere shortening (e.g. TERT and TERC) or surfactant protein mutations (e.g. SFTPC)1. 
Heterozygous RTEL1 mutations were identified in four separate families with FPF.  Patients with the 
RTEL1 mutation were compared to healthy, age-matched cohorts (n=13)1.  Each individual studied was a 
male smoker.  Missense mutations comprised three of the four RTEL1 mutations while the other was due 
to a duplication mutation1.   The duplication mutation led to a frameshift and caused a premature stop 
codon1.  Structural modelling revealed that two of the missense mutations were likely to disrupt DNA 
binding or ATP hydrolysis1.  Individuals with the RTEL1 mutation also showed decreased telomere length 
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compared to the healthy cohorts, suggesting that the mutation induces premature telomere shortening1.  This 
study suggested that heterozygous mutations in RTEL1 are a potential genetic basis for FPF.   
RTEL1 mutations were linked to telomere length in a study done by Stuart et al. (2015) that was 
similar to Kassengiesser et al. (2015) study.  Stuart et al. (2015) found that probands with RTEL1 mutations 
demonstrated higher percentages of short telomere lengths than the control8.  Telomere length was also 
measured in this study and, similar to the previously mentioned study, it was noted that the mean telomere 
lengths of related individuals, who did not inherit the RTEL1 mutation, were shorter than those of unrelated 
individuals.  However, the mean telomere lengths of the related individuals were longer than those affected 
by the RTEL1 mutation8.  The findings from these two studies suggest that RTEL1 gene mutations play a 
significant role in telomere shortening, largely by missense mutation, resulting in the onset of FPF.   
TERT Mutation 
Mutations in TERT apparently underlie inheritance of FPF in 8-15% of cases5.  Telomerase reverse 
transcriptase, TERT, is one of two essential components that makes up telomerase, a ribonucleoprotein that 
synthesizes telomere DNA5.  Several studies have suggested that heterozygous mutations in TERT cause 
telomere shortening via haploinsufficiency5.  As discussed previously, a mutation in TERT is also found to 
cause dyskeratosis congenita, a disorder in which 20% of affected individuals develop FPF4. The link 
between TERT and FPF has been observed in several studies.  
In a study by Tsakiri et al. (2007), 46 individuals, with a family history of FPF were identified and 
their genes sequenced for TERT mutations and five missense mutations were identified.  As expected, these 
mutations produced significantly decreased levels of telomerase activity4.  Compared to healthy family 
members, the mean telomere length was significantly shorter for those individuals with heterozygous TERT 
mutations. When comparing heterozygous affected individuals to their asymptomatic carrier family 
members, telomere length was considerably shorter in the affected individuals4. This suggests that 
5
individuals with TERT mutations show a shortened telomere length and decreased levels of telomerase, 
when compared to healthy individuals as well as healthy family members.  
Another study showed similar results to the study discussed previously.  Alder et al. (2011) studied 
two families with a history of FPF present and observed a pattern of shortened telomere length in individuals 
affected by TERT mutations compared to related, healthy individuals5.  In six of nine individuals with the 
TERT mutation, telomere length fell below the first percentile, a range specific for the presence of 
telomerase maintenance defects5.  In four related individuals, telomere length fell below the 10th percentile 
while two individuals fell below the first percentile, indicating TERT mutations were the cause of shortened 
telomere length5.  Affected individuals with TERT mutations showed an overall decrease in telomerase 
activity, thus telomere shortening was expected.  These results suggest that heterozygous TERT mutations 
are a potential genetic cause of the onset of FPF.   
MUC5B Mutation 
Mucins (e.g. MUC5B) are glycosylated proteins responsible for giving mucus its viscoelastic 
properties.   Mucus is important in removing debris and trapped particles, including bacteria, dying 
epithelial cells, and leukocytes13.   MUC5B is present most abundantly in the distal airways of the respiratory 
tract, and since IPF presents with abnormalities in the distal airway it would make sense that a mutation in 
MUC5B could contribute to the development of IPF.  Dual immunofluorescence analysis of MUC5B 
showed that in 80% of patients with IPF there was an overabundance of MUC5B cells present in the distal 
airways.  Further evidence supporting MUC5B mutations is that epithelial cells that express MUC5B are 
the dominant mucin-expressing cell type in microscopic honeycomb cysts, which are filled with MUC5B 
protein13.  
Overexpression of MUC5B would result in excess mucus, and this has been the proposed 
mechanism contributing to IPF.   Specifically, excess MUC5B is thought to cause the development of IPF 
resulting from excessive lung injury and non-repair13.  Excess mucus causes the onset of many respiratory 
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disease, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (CF), so it is 
entirely plausible that excess mucus could contribute to the onset of IPF.  The mechanism of action is 
unclear, but several hypotheses have been proposed in multiple studies.  
The first hypothesis is that because MUC5B reduces mucosal host defense and lung clearance of 
inhaled particles and debris which may lead to scar tissue formation which is characteristic of IPF13.  A risk 
factor identified with IPF is cigarette smoking, so it is reasonable to assume that inhaled particles from the 
smoking might cause defects in mucosal host defense and may lead to formation of scar tissue.  The second 
hypothesis is that excessive MUC5B interferes with alveolar repair13.  Alveolar type II epithelial cells 
expand after injury to help repair damage, but with excess MUC5B, this process may be impaired.  The 
proposed mechanism is that MUC5B potentially interferes with interactions between alveolar cells and the 
matrix or interferes with surfactant properties13.  
Overall, it is suggested that excessive MUC5B in the distal airways enhances injury and disrupts 
repair of alveoli.   The two proposed hypotheses could even potentially both contribute to IPF.   The 
probable role of MUC5B in interfering with surfactant properties could link to the much-studied SFTPC 
mutation that is found in several cases of FPF.  
SFTPC Mutation 
Surfactant protein C mutations (SFTPC) are one of the more commonly found in surfactant 
metabolism genes.  SFTPC is a hydrophobic protein, exclusively produced by alveolar type II epithelial 
cells11,12.   Surfactant protein C enhances the surface tension-reducing capacities of alveolar fluid and is 
dependent on ABCA311.  Surfactant protein C is synthesized by alveolar type II cells, allowed to mature, 
and then are released into the alveoli with other proteins and phospholipids11,12.  Mature surfactant protein 
C is stored and then secreted into the alveolar space.  Once in the lung, surfactant protein C is expressed 
only in alveolar type II epithelial cells11,12.  Surfactant protein C has domains called BRICHOS, which auto-
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protect the peptide from aggregation and 75% of all mutations reported in SFTPC are in a BRICHOS 
domain12.  One particular study focused on the potential link between BRICHOS and SFTPC.  
Ono et al. (2011) studied three generations of a Japanese family, in which six of the individuals 
were diagnosed with FPF.  In order to determine the potential genetic link, this group sequenced the 
patients’ SFTPC and ABCA3 genes12.  Sequencing revealed a novel heterozygous mutation in the 
BRICHOS domain of the SFTPC gene while no mutations were present in the ABCA3 genes.  Western 
blotting comparing the normal and mutant SFTPC genes showed an increased amount of surfactant C 
protein compared to the normal genes as well as increased expression of unfolded protein response proteins 
and chaperone proteins12.  These proteins were then shown to be upregulated.  The results suggest that 
mutations in the BRICHOS domain of the SFTPC gene lead to apoptosis which then injured type II alveolar 
epithelial cells, inducing FPF12.  
Mutant SFTPC genes were the focus of a Dutch study as well in which 22 unrelated patients with 
FPF were identified from a cohort of 229 patients with idiopathic pulmonary fibrosis (IPF)11.  SFTPC was 
sequenced in 20 of the patients with FPF and in 20 patients with IPF11.  Sequencing of ABCA3 was also 
performed in the patients with FPF.  In 5 of the 20 unrelated patients with FPF, a deletion mutation in 
SFTPC was detected while no mutations were detected in the 20 patients with IPF11.  Two variant mutations, 
resulting in amino acid substitutions, were found in ABCA3 genes of adult patients with FPF.   
CT scans revealed the typical pattern of interstitial pneumonia and nodular septa thickening along 
with multiple lung cysts [Fig 2]—this is often typical of adult SFTPC mutation carriers11.  The results 
indicate that mutations in SFTPC were the major cause of FPF development in the cohort.  While RTEL1, 
TERT, and SFTPC are relatively known mutations associated with FPF, more novel mutations, such as 
PARN and ZCCHC8, have also been investigated.    
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Figure 2. Computerized tomography (CT) scans of adult, SFTPC mutation carriers shown above.  
 
PARN Mutation 
PARN, encoding polyadenylation-specific ribonuclease deadenylation nuclease, is a 3’ 
exoribonuclease, not previously implicated in disease or telomere maintenance, but has recently been 
connected to the potential onset of FPF8.  In a 2015 study, PARN was shown to have six damaging variants 
in individuals with FPF, but zero mutations in the controls8.  PARN mutations in this same study were 
shown to act similar to RTEL1 mutations in that six out of the seven individuals with either mutation showed 
a shortened telomere length compared to the control and their relatives8.  The PARN mutation is a relatively 
understudied mutation, so while the results from the 2015 study show support for the PARN mutation in the 
onset of FPF, the mechanism is unclear.  However, PARN has been shown to assist in the maturation of 
snoRNAs which are known to associate with four proteins, three of which have mutations in the genes 
encoding them, causing dyskeratosis congenita8.    
ZCCHC8 Mutation 
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Another novel mutation recently discovered as a potential genetic cause of FPF involves a mutation 
in ZCCHC8 which encodes for a zinc-knuckle containing protein.  In terms of its mechanism, ZCCHC8 is 
largely associated with TERC, another gene shown to cause an estimated 15% of FPF cases14.  A study 
conducted by Gable et al. (2019) showed that the link between ZCCHC8 and TERC plays a pivotal role in 
causing FPF.  The study focused on an individual with low levels of TERC, telomere shortening, and a 
family history consistent with PF14.  
Functional testing of ZCCHC8 revealed that all three mutation carriers had 50% lower 
ZCCH8protein levels compared to the control14.  CRISPR/Cas9 editing was used to detect the effect of 
ZCCHC8 on TERC, and the results showed that decreased levels of the mutated gene corresponded to 
decreased levels of TERC14.  Using telomere repeat amplification protocol, telomerase activity was 
measured.  The ZCCHC8-deficient cells showed significantly decreased activity, thus collective the data 
indicates that the gene is necessary for TERC maturation and for proper telomerase functioning14. 
Conclusion 
 While the genetics contributing to familial pulmonary fibrosis are partially known, there are still a 
plethora of mutations that could underlie the onset of the disease.  The importance of understanding the 
genetics behind the disease is vital because there are no known treatments for FPF.  The onset of the disease 
comes on rapidly and the disease seems to progress remarkably quickly after diagnosis.  Because the 
symptoms can resemble most respiratory illnesses, it is important to understand the characteristic patterns 
observed in FPF— nodular thickening, especially in the case of surfactant mutations, interstitial pneumonia, 
and in a majority of cases, honeycomb lung.  Future research should focus on the mechanisms underlying 
how mutations such as MUC5B and RTEL1 affect other cells causing development of FPF.  
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